The only known egg of the Night Parrot? A molecular and morphometric assessment of an alleged egg from the Tanami Desert

The Night Parrot Pezoporus occidentalis is a much sought-after, recently ‘rediscovered’, endangered nocturnal parrot, endemic to arid Central Australia. Very little is known of its ecology, and its eggs have never been formally described. The literature on the eggs of the Night Parrot is collated here, and the provenance of an alleged Night Parrot egg found in the Tanami Desert, Northern Territory, in 1983 was assessed using DNA analysis and physical characteristics. Anecdotal reports from the late 19th–early 20th Century indicate that the Night Parrot lays a clutch of two to six roundish, white eggs. We suggest that its eggs are probably similar to and slightly larger than those of its congener, the Ground Parrot P. wallicus. The alleged Night Parrot egg was definitively identified by mitochondrial DNA analysis to be from the Brown Quail Synoicus ypsilophorus. This represents the first evidence of breeding by this species in the Tanami Desert, and lays to rest a long-standing misconception regarding the parrot

Roper River (Elsey And Moroak Stations) Freshwater Fishes Survey

Made available by the Northern Territory Library via the Publications (Legal Deposit) Act 2004 (NT).Date:2008-1

Examiner comment on theses that have been revised and resubmitted

Since the 1980s there has been a growing interest in the 'visibility' of doctoral processes, particularly with respect to supervision, but more recently with respect to examination. Questions are being asked that encompass a range of issues from examiner selection through to the rigour and credibility of assessment procedures. Many commentators have pointed out that doctoral examination, and doctoral study generally, is an exceedingly complex phenomenon that has yet to be subject of sustained and systematic research. How students achieve success, the role supervisors play in getting a candidate's thesis to submission stage, or through an oral defence, and what constitutes quality in postgraduate research are all areas that are receiving attention in the field of research training in higher education

Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries

International audienceAbstract Introduction The Ebola virus disease (EVD) outbreak in 2014–2016 in West Africa was the largest on record and provided an opportunity for large clinical trials and accelerated efforts to develop an effective and safe preventative vaccine. Multiple questions regarding the safety, immunogenicity, and efficacy of EVD vaccines remain unanswered. To address these gaps in the evidence base, the Partnership for Research on Ebola Vaccines (PREVAC) trial was designed. This paper describes the design, methods, and baseline results of the PREVAC trial and discusses challenges that led to different protocol amendments. Methods This is a randomized, double-blind, placebo-controlled phase 2 clinical trial of three vaccine strategies against the Ebola virus in healthy volunteers 1 year of age and above. The three vaccine strategies being studied are the rVSVΔG-ZEBOV-GP vaccine, with and without a booster dose at 56 days, and the Ad26.ZEBOV,MVA-FN-Filo vaccine regimen with Ad26.ZEBOV given as the first dose and the MVA-FN-Filo vaccination given 56 days later. There have been 4 versions of the protocol with those enrolled in Version 4.0 comprising the primary analysis cohort. The primary endpoint is based on the antibody titer against the Ebola virus surface glycoprotein measured 12 months following the final injection. Results From April 2017 to December 2018, a total of 5002 volunteers were screened and 4789 enrolled. Participants were enrolled at 6 sites in four countries (Guinea, Liberia, Sierra Leone, and Mali). Of the 4789 participants, 2560 (53%) were adults and 2229 (47%) were children. Those < 18 years of age included 549 (12%) aged 1 to 4 years, 750 (16%) 5 to 11 years, and 930 (19%) aged 12–17 years. At baseline, the median (25th, 75th percentile) antibody titer to Ebola virus glycoprotein for 1090 participants was 72 (50, 116) EU/mL. Discussion The PREVAC trial is evaluating—placebo-controlled—two promising Ebola candidate vaccines in advanced stages of development. The results will address unanswered questions related to short- and long-term safety and immunogenicity for three vaccine strategies in adults and children. Trial registration ClinicalTrials.gov NCT02876328 . Registered on 23 August 2016